Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 ISIN · KYG1821D1097 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings
2026-05-06 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 100% confidence The document is titled 'Environmental, Social and Governance Report 2025' and is published by CANbridge Pharmaceuticals Inc. It explicitly states it is an ESG report covering environmental, social, and governance performance for the year 2025. The content includes detailed discussion of ESG strategy, governance, stakeholder engagement, and sustainability targets. It references compliance with ESG Reporting Code and IFRS Sustainability Disclosure Standards. The document is not an annual report, earnings release, or any other financial report but focuses on ESG factors. Therefore, it fits the category of Environmental & Social Information (ESG) report.
2026-04-29 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' for CANbridge Pharmaceuticals Inc. It contains detailed sections typical of an annual report, including Definitions, Corporate Information, Financial Highlights, Chairman's Statement, Management Discussion and Analysis, Biographies of Directors and Senior Management, Report of Directors, Corporate Governance Report, Independent Auditors' Report, and full Consolidated Financial Statements with Notes. The reporting period is clearly stated as the year ended December 31, 2025. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data, management discussion, and auditor's report confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-29 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 91% confidence The document is a corporate stock exchange announcement detailing the grant of share options and restricted share units under the company’s Post-IPO equity incentive schemes. It is not an earnings release, management report, AGM presentation, or legal update. It does not announce actual share repurchases nor insider trades, but rather a planned issuance of equity-linked instruments requiring shareholder approval. This falls squarely under “Share Issue/Capital Change” (SHA).
2026-04-13 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026
Regulatory Filings Classification · 90% confidence The document is the HKEX FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules, detailing movements in authorised and issued share capital, share options, capital changes, and public float confirmation. It is a recurring regulatory submission to the stock exchange and does not fit specialized categories like an earnings release, AGM materials, or a proxy statement. Therefore, it is classified as a general regulatory filing.
2026-04-09 English
(Revised) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026
Share Issue/Capital Change Classification · 85% confidence The document is an HKEX Form FF301 monthly return detailing movements in authorised share capital, issued shares (including share option exercises), and other capital changes of the issuer. It is not an earnings release, management change, or AGM material, but a regulatory submission focused on share issuance and capital structure movements. Therefore it best fits the “Share Issue/Capital Change” category (Code: SHA).
2026-04-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.